CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that favorable results from a Phase 1b/2 clinical trial with aldoxorubicin (formerly INNO-206) in patients with advanced soft tissue sarcoma will be featured in a poster and discussion presentation at the Connective Tissue Oncology Society (CTOS) 17 th Annual Meeting on November 15 in Prague, Czech Republic.
The abstract, “Aldoxorubicin (INNO-206) is an active drug for the treatment of relapsed or refractory soft tissue sarcomas,” will be presented by the clinical trial’s principal investigator Dr. Sant Chawla, M.D., F.R.A.C.P. Dr. Chawla, a world renowned expert in the treatment of soft tissue sarcomas, is Director of the Sarcoma Oncology Center in Santa Monica, Calif. The Phase 1b/2 clinical trial results, first announced in early June 2012 at the American Society of Clinical Oncology (ASCO) conference, showed clinical benefit (defined as partial response and stable disease of more than four months following up to eight cycles of treatment) with aldoxorubicin at the maximum tolerated dose in 10 of 13 evaluable patients with advanced, metastatic soft tissue sarcomas who had either not responded or relapsed after receiving one to three prior chemotherapies. Eight of the 13 patients had been treated previously with doxorubicin.
“We are excited to share the powerful data from our aldoxorubicin clinical trial with experts from the international oncology community at this preeminent sarcoma conference, as well as at the upcoming ESMO 2012 Congress in Vienna, Austria,” said Steven A. Kriegsman, CytRx President and CEO. “The results from this clinical trial are impressive, especially given that these patients had failed prior chemotherapy regimens. Further, there were no observed cardiac toxicities with aldoxorubicin in this clinical trial, with cardiac toxicity considered a major dose-limiting factor for standard doxorubicin. Again, we thank Dr. Chawla for his valuable time to present at these international conferences.”